Clinical trial · Observational
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators want to compare the use of MRI with PET/CT preformed after 1 hour and 3 hours in preoperative assessment of resectability. The investigators' hypothesis is that dual time PET/CT performed at 60 and 180 minutes will increase the diagnostic accuracy of conventional PET (performed at 60 minutes) in preoperative assessment of resectability. Further more the investigators suggest that the GLUT/G6Pase index correlates to the SUVmax. And retention index (RI, see Methods - PET protocol) is a prognostic marker in ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT(3hours] | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Suspected ovarian cancer
- description
- dual time PET/CT
- interventionNames
- Other: PET/CT(3hours]
Primary outcomes (1)
- measure
- Accuracy in MR, PET/CT 1h and 3h preoperative assessment of ovarian cancer resectability(PET/CT[1]) of the radioactive tracer FDG with PET/CT performed after 3 hours (PET/CT[3]) in a group of patients with high suspicion of ovarian cancer
- timeFrame
- 2 years
- description
- At biweekly multidisciplinary meetings patient resectability is assessed based on disease spread by using conventional PET/CT and MR. The MR, PET \[1 hour\] vs. PET \[3 hours\] in assessment of disease spread compared to peroperative findings.
Secondary outcomes (1)
- measure
- Compare SUVmax with the expression of GLUT1, hexokinase and G6Pase in tumors
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspicion of ovarian cancer * Referred to Department of Gynecology, OUH Exclusion Criteria: * Unable to corporate to MR * Diabetes Mellitus * Prescan glucose level \> 10 mmol/l (PET) * non-ovarian cancer (incl. benign)
References
Publications (0)
Data not yet available